SecBot SecBot
SECBOTREPLAY Home › Report › PROF

PROF · Profound Medical announced new CAPTAIN trial data showing statistically…

Profound Medical Corp. · 8-K filed Jul 24, 2026 at 11:58 ET

At the news

BULLISHIMPACT 6/10

8-K filed Jul 24, 2026 at 11:58 ET

Profound Medical announced new CAPTAIN trial data showing statistically significant superior penile length preservation with the TULSA Procedure vs robotic radical prostatectomy (no median change vs 0.65 cm reduction at 1 month, p<0.001). This adds to previously reported safety endpoint advantages in erectile function and urinary continence, strengthening the clinical value proposition for TULSA.

  • CAPTAIN trial: no median change in penile length at 1 month after whole-gland TULSA vs 0.65 cm median reduction after robotic RP
  • Between-arm difference statistically significant (0.42 cm, p<0.001)
  • Data presented at Society of Robotic Surgery Annual Meeting, July 24, 2026
  • Previously announced CAPTAIN primary safety endpoint showed TULSA superiority in preserving erectile function and urinary continence at 6 months

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access